A rare hematological disease characterized by maternal alloimmunisation against fetal platelet antigens that are inherited from the father and different from those present in the mother, and usually p...
Comprehensive, easy-to-understand information about this condition
How we create this content →Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
The limited documentation surrounding fetal and neonatal alloimmune thrombocytopenia is largely due to its rarity, affecting only a small number of newborns. This low prevalence restricts the ability to conduct extensive clinical studies and gather comprehensive data. Additionally, the complexity of maternal-fetal interactions and the lack of identified genetic markers further complicate the understanding of the condition.
To navigate fetal and neonatal alloimmune thrombocytopenia, consider consulting a hematologist with expertise in neonatal blood disorders. They can provide specialized care and management strategies. Additionally, the patient organization Naitbabies (https://naitbabies.org) offers resources and support for affected families. You may also explore opportunities to participate in patient registries or natural history studies to contribute to the understanding of this condition.
Currently, there are two active clinical trials investigating treatments for fetal and neonatal alloimmune thrombocytopenia. Notably, the orphan drugs nipocalimab and a recombinant human IgG monoclonal HPA-1a antibody are in development. These investigational therapies aim to address the underlying immune response leading to thrombocytopenia. For more details on the ongoing trials, you can visit ClinicalTrials.gov and search for 'fetal and neonatal alloimmune thrombocytopenia'.
Actionable guidance for navigating care for fetal and neonatal alloimmune thrombocytopenia
To navigate fetal and neonatal alloimmune thrombocytopenia, consider consulting a hematologist with expertise in neonatal blood disorders. They can provide specialized care and management strategies. Additionally, the patient organization Naitbabies (https://naitbabies.org) offers resources and support for affected families. You may also explore opportunities to participate in patient registries or natural history studies to contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the fetal and neonatal alloimmune thrombocytopenia community
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
1 peer-reviewed source from PubMed
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.